There is no standard treatment for relapsed follicular lymphoma (FL). Although platinum-based combinations are one of the most used treatments, few data have been reported in this setting. Our aim was to analyse R-ESHAP efficacy in relapsed FL patients. We retrospectively analysed 80 FL patients treated with R-ESHAP in the first or successive relapses. Responding patients received a stem cell transplantation following R-ESHAP. Seventeen histologically transformed patients were included. Median age was 50 years. At R-ESHAP initiation, 85% of the patients were in an advanced stage, 28% had a bulky disease and 40% had increased LDH. There were no statistically significant differences between POD24 and non-POD24 patients in terms of response to R-ESHAP (ORR 72% vs. 93%, p = 0.109). When analyzing R-ESHAP efficacy according to the response to the immediately previous line, patients achieving CR or PR had better CR rates to R-ESHAP than those who did not respond (CR of 57% vs. 15%, respectively, p = 0.009), as well as differences in OS (7.2 vs. 1.4 years, p < 0.0001) and in PFS (2.1 vs. 0.3 years, p < 0.0001). R-ESHAP is an effective treatment in relapsed FL patients who respond to the previous line and has to be considered as an adequate alternative for some patients.

复发性滤泡性淋巴瘤 (FL) 没有标准治疗方法。尽管铂类组合是最常用的治疗方法之一，但在这种情况下报告的数据很少。我们的目的是分析 R-ESHAP 在复发性 FL 患者中的疗效。我们回顾性分析了 80 名首次或连续复发时接受 R-ESHAP 治疗的 FL 患者。有反应的患者在 R-ESHAP 后接受了干细胞移植。包括十七名组织学转化的患者。中位年龄为 50 岁。在 R-ESHAP 开始时，85% 的患者处于晚期，28% 的患者患有大块病，40% 的患者 LDH 增加。就 R-ESHAP 的反应而言，POD24 和非 POD24 患者之间没有统计学显着差异（ORR 72% vs. 93%，p= 0.109）。根据对前一行的反应分析 R-ESHAP 疗效时，达到 CR 或 PR 的患者对 R-ESHAP 的 CR 率高于未反应的患者（CR 分别为 57% 和 15%，p = 0.009 )，以及 OS（7.2 与 1.4 年，p < 0.0001）和 PFS（2.1 与 0.3 年，p < 0.0001）的差异。R-ESHAP 是一种有效治疗复发 FL 患者的方法，这些患者对先前的治疗线有反应，并且必须被视为对某些患者来说是一种适当的替代方法。